- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Americans know little about generics
Study finds that Americans have limited understanding when it comes to the cost and effectiveness of generic drugs.
Many Americans still have limited understanding when it comes to the cost, ingredients and effectiveness of generic drugs. The current economic crisis is also affecting consumer prescription drug use, according to a study conducted by Opinion Research Corp. on behalf of Prescription Solutions.
“Unfortunately, studies have shown that people aren’t always taking medications as prescribed and high cost can be a factor,” says Brian Solow, MD, vice president and medical director, clinical programs for Prescription Solutions.
“Medication compliance is important to ensure the good health of employees and health plan members and to manage costs associated with noncompliance such as ER visits and cascading illnesses,” Dr. Solow adds.
Key findings of the survey include:
• Nearly one-third of Americans don’t know or believe that generics have the same active ingredients and effectiveness as brand-name drugs.
• Two-thirds do not understand the true cost differences between brand-name drugs and generics.
• 71% of consumers remain concerned about drug costs-with more than one in four (27%) having either delayed filling, not filled, or not taken as directed a prescription drug in order to save funny. Further, 21% say they have talked to their doctor recently about switching to a less-expensive drug.
• 57% say they take prescription drugs on a weekly basis. Of those who do so, 83% take generics. Further, among those who take generics, 82% say they do so because of the lower cost.
• Of those who do not take generics on a weekly basis, 58% say it is because there is no generic available for the drug they need.
• 64% say their doctor recommended generics, and 43% say their pharmacist recommended them.
• Of those who do not take generics on a weekly basis, 58% say they would if their pharmacist brought a generic to their attention as a less-expensive, identical substitute; and 52% say their doctor would have to recommend it.
“From both experience and clinical research we know that affordable generics help people manage diseases from diabetes to high blood pressure by remaining compliant with prescribed medications,” Dr. Solow adds.
The study included 1,000 adults (500 men and 500 women), 18 years of age and older, and living in private households in the continental United States.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
In this second part of a video series, AMCP CEO Susan Cantrell addressed the impact of high prescription drug prices on underserved communities, highlighting disparities in access caused by the pandemic's effects on minority populations. On the industry blame debate, she urged collaborative solutions, mentioning AMCP's engagement with diverse stakeholders to find comprehensive, patient-centric solutions and advocate for policy changes like the MVP Act to address rising costs and access challenges.
Read More
